NYSE:HIMSHealthcare
A Look At Hims & Hers Health (HIMS) Valuation After Novo Nordisk Deal And GLP 1 Market Shift
Hims & Hers Health (HIMS) is back in focus after renewing its partnership with Novo Nordisk, giving the telehealth platform access to branded weight loss drugs as FDA peptide policy changes reshape the GLP 1 market.
See our latest analysis for Hims & Hers Health.
After a sharp run that produced a 39.33% 7 day share price return and a 35.15% 30 day share price return, Hims & Hers is giving back some ground. The latest 4.03% single day share price decline reflects investors reassessing...